Static list review decision – August 2017
Decision to transfer the guidance to the static guidance list
Further to our letter of 26 June 2017, we would like to update you on the decision made regarding the review of the existing guidance on TA317; Prasugrel with percutaneous coronary intervention for treating acute coronary syndrome.
The Institute was proposing the guidance should be transferred to the ‘static guidance list’.
After consideration of all of the comments received during the Review Consultation, the Technology Appraisals programme has decided to proceed with this proposal.
Consequently, the guidance will now be transferred to the static guidance list. Topics on the static list can be considered for review if any new evidence becomes available that is likely to lead to a change in the existing recommendations.
This page was last updated: